The first patient with advanced gastric and gastroesophageal cancer has been dosed in a trial combining PT886 with ...

Leads Biolabs’ LBL-024 receives Breakthrough Therapy Designation from China NMPA to treat extrapulmonary neuroendocrine carcinoma: Nanjing, China Thursday, October 10, 2024, 10: ...

The deal allows MSD to license one or more therapies against inflammatory diseases developed using the UK biotech’s ...

Regeneron Pharmaceuticals demonstrates a stronger financial position compared to its top 4 peers in the sector. With a lower debt-to-equity ratio of 0.1, the company relies less on debt financing and ...

DelveInsight's CD47 Inhibitors Market Insights report includes a comprehensive understanding of current treatment practices, ...

Discover the major biotech partnerships, collaborations and mergers and acquisitions that made headlines in September 2024.

This article explores the revolution in new drug modalities and the challenges around effective data strategies to support AI ...

Diagonal is advancing its lead program to treat the underlying cause of hereditary hemorrhagic telangiectasia (HHT)WATERTOWN, Mass., Oct. 0 ...

BioAtla faces a tight cash runway until Q3 2025, raising concerns about dilution and short-term stock headwinds. Find out why ...